ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2184

Development of Salivary Gland Organoids to Study Sjögren Syndrome

Loïc Meudec1, Negaar Goudarzi2, Juliette Pascaud3, Fanny Jaulin2, Xavier Mariette4 and Gaetane Nocturne5, 1CHU Kremlin-Bicêtre, Rheumatology, Le Kremlin-Bicêtre, France, 2INSERM UMR 981, Institut Gustave Roussy, Villejuif, France, Villejuif, France, 3Center for Immunology of Viral Infections and Autoimmune Diseases, INSERM UMR 1184, FHU CARE, Université Paris-Saclay, Le Kremlin-Bicêtre, France, 4Université Paris-Saclay, Le Kremlin-Bicêtre, France, 5APHP, Le Kremlin-Bicêtre, France

Meeting: ACR Convergence 2023

Keywords: immunology, Sjögren's syndrome, Tissue Engineering

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2177–2194) Sjögren’s Syndrome – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Sjögren disease (Sjo) is an autoimmune disease characterized by the infiltration of exocrine glands by immune cells, especially salivary glands (SG). SG epithelial cells (SGEC) are involved in Sjo pathogenesis, mostly through their crosstalk with immune cells. The primary 2D culture of SGEC derived from Sjo patients has been very useful to better understand Sjo pathogenesis but does not recapitulate the complexity of the SG and lacks epithelial readout, highlighting the necessity to develop new relevant models. Our objective was to develop and characterize differentiated organoids of SGEC derived from minor salivary gland (MSG) of Sjo patients and controls.

Methods: We included Sjo patients fulfilling the ACR/EULAR 2016 criteria and controls with sicca syndrome. MSG were firstly dissociated enzymatically, then encapsulated in Matrigel© and cultured in Growth Expansion Medium (GEM) containing growth factors, until organoids formation. Organoids were passaged every 7-11 days for self-renewal and cultured in a Differentiation Medium (DM) inhibiting the NOTCH pathway, to develop mature organoids. Proliferation was assessed by cell counting and SGEC markers were investigated by RT-qPCR and immunofluorescence.

Results: Ten patients were included: 8 controls and 2 Sjo patients. Organoids with an average size of 100-200 µm were forming and differentiating in both patients and controls (Figure 1A). The mean culture duration was 2.7 ± 1.7 months and was continued for up to 6 months. The self-renewal capacity of organoids in expansion condition was comparable between the two groups, as evidenced by comparable growth curves for the 2 groups (Figure 1B) and the high expression of the Ki67 marker in the periphery of organoids, arguing an active cell proliferation (Figure 1C). We then differentiated the organoids. Mature organoids highly expressed the ductal markers CK7/CK18 and, to a lesser degree, the acinar markers AQP5 and α-amylase, in both Sjo patients and controls (Figure 1D). We confirmed these results in RNA expression, showing an enhanced expression of acinar and ductal markers with DM compared to GEM (Figure 1E). Last, we have performed one preliminary experiment in which we have been able to develop immune-organoids by adding PBMC in the organoids (Figure 1F). Work is still in progress to assess the impact of immune cell infiltrate on organoid characteristics.

Conclusion: We established a culture system of SG organoids from MSG in Sjo patients and controls with long term expansion and maturation markers expression. Additional investigations are ongoing to assess the functionality of the organoids and to develop immune-organoids for assessing the impact of adding immune cells in the system. Bibliography 1. Pringle S, et al. Arthritis Rheumatol. 71(1):133‑42.

Supporting image 1

Figure 1: Characterization of SG organoids from Sjo patients and control
(A) SG organoids in expansion and differentiation captured by photonic microscopy. (B) SGEC expansion by the ratio between cell count at seeding and at passaging. (C) Ki67 expression in organoids cultured in GEM. (D) CK7/CK18 (ductal), AQP5 and α-amylase (acinar) expression in organoids cultured in DM. (E) CK7, AQP5, and α-amylase RNA expression in SG organoids cultures in GEM and DM (n=3). (F) Infiltration of SG organoid by CFSE-labelled PBMC.


Disclosures: L. Meudec: None; N. Goudarzi: None; J. Pascaud: None; F. Jaulin: None; X. Mariette: AstraZeneca, 2, 6, BMS, 2, 6, Galapagos, 2, 6, GSK, 2, 6, Novartis, 2, 6, Pfizer, 2, 6; G. Nocturne: None.

To cite this abstract in AMA style:

Meudec L, Goudarzi N, Pascaud J, Jaulin F, Mariette X, Nocturne G. Development of Salivary Gland Organoids to Study Sjögren Syndrome [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/development-of-salivary-gland-organoids-to-study-sjogren-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-salivary-gland-organoids-to-study-sjogren-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology